Thuja Capital

Portfolio 2009

Company: Fabpulous B.V. - Visit website

Fund: Thuja Capital Healthcare Fund I

Year: 2009

Status: Active

Fabpulous develops a handheld disposable plasma separation device with embedded in vitro diagnostic test capability (lateral flow). The first application is a rapid h-FAPB test as an aid in the early diagnosis of a heart infarct.

Company: Cavadis B.V. - Visit website

Fund: Thuja Capital Healthcare Seed Fund I

Year: 2009

Status: Active

Cavadis is a biomarker company aiming to develop in vitro diagnostics for cardiovascular risk assessment.

Browse our portfolio of companies by Fund, Year or Status

• Fund
  • AlpInvest Life Sciences
  • Thuja Capital Healthcare Fund I
  • Thuja Capital Healthcare Fund II
  • Thuja Capital Healthcare Seed Fund I
  • Thuja Capital Healthcare Seed Fund II

• Year
  • Prior to 2008
  • 2008
  • 2009
  • 2010
  • 2011
  • 2012
  • 2013
  • 2014
  • 2015
  • 2016
  • 2017
  • 2018

• Status
  • Active
  • Realized

• News

  • 31 January, Eindhoven, The Netherlands – Salvia BioElectronics B.V. announced today that the Brabant Startup Fund (BSF) joins the current investment syndicate led by Thuja Capital and Brabant Development Agency (BOM). Read further …

  • 10 December 2018, Nijmegen, The Netherlands – ATRO Medical BV has obtained permission from the Healthcare and Youth Inspection to implant the meniscal prosthesis Trammpolin® in eighteen patients. ATRO Medical BV does this together with Radboudumc, the Maastricht UMC+ and the Sint Maartenskliniek. Read further …

  • 2 November 2018, Maastricht, The Netherlands – Cristal Therapeutics has appointed Dr. Axel Mescheder to the role of Chief Executive Officer (CEO) with immediate effect. He will also serve as Chief Medical Officer (CMO). Read further …

• Events

  • 24-28 June 2019 – BioBusiness Summer School time in Amsterdam! Many interesting lecturers, among whom Michel Briejer who will speak about venture capital.